Researchers have found that antibodies against the human papillomavirus (HPV) may help identify individuals who are at greatly increased risk of HPV-related cancer of the oropharynx, which is a portion of the throat that contains the tonsils.
[More]
Icahn School of Medicine at Mount Sinai researchers will present several landmark studies at the 2013 American Society of Clinical Oncology meeting May 31-June 4, 2013 in Chicago, including data on the likelihood of spousal human papillomavirus oral infection, new gene signatures in melanoma, and issues with high readmission rates after cancer surgery.
[More]
Infection with the human papillomavirus (HPV) can lead to cervical cancer via a preliminary stage - that of cervical intraepithelial neoplasia (CIN). In Europe 205,000 women every year are affected by this condition, most of them are aged between 25 and 30 years. Since in many cases slight manifestations of the disease (CIN 1) heal spontaneously, mostly no treatment is given but self-healing monitored by means of rigorous and continuous check-ups.
[More]
A new measure of the heterogeneity - the variety of genetic mutations - of cells within a tumor appears to predict treatment outcomes of patients with the most common type of head and neck cancer.
[More]
A new Boston University School of Medicine study has found that low-income and minority parents may be more receptive to vaccinating their daughters against Human Papillomavirus, while white, middle-class parents are more likely to defer the vaccination.
[More]
In Kenya, women face a cervical cancer mortality rate that is approximately 10 times as high as in the United States.
[More]
A common virus known to cause cervical and head and neck cancers may also trigger some cases of lung cancer, according to new research presented by Fox Chase Cancer Center at the AACR Annual Meeting 2013 on Wednesday, April 10.
[More]
Women with HIV acquire cancer-causing forms of the human papillomavirus (HPV) that are not included in the current HPV vaccines Gardasil and Cervarix, according to new research from Fox Chase Cancer Center being presented at the AACR Annual Meeting 2013 on Sunday, April 7.
[More]
Even though the human papillomavirus (HPV) is a risk factor for certain head and neck cancers, its presence could make all the difference in terms of survival, especially for African Americans with throat cancer, according to a newly published study from Henry Ford Hospital in Detroit.
[More]
Trovagene, Inc., today announced the commercial availability of its urine-based HPV-HR (high-risk) assay, a molecular human papillomavirus test.
[More]
Researchers at Moffitt Cancer Center and colleagues at the University of Florida studied health care providers to determine the factors associated with disparities in Human Papillomavirus (HPV) vaccination among girls, ages 9 to 17, from low-income families.
[More]
30 years into the HIV epidemic, there is no vaccine in sight. Yet, even though there are fantastic and effective cheap and universally available drugs, and a treatment as prevention strategy is known to work, people do not wish to get tested for HIV! If everyone got tested, and treated, we could have brought the infection under control a long time ago!
[More]
Completion rates for the human papillomavirus (HPV) vaccine series across both genders continue to remain alarmingly low nearly seven years after its introduction, suggesting that better patient education and increased public vaccine financing programs are needed, according to new research from the University of Texas Medical Branch (UTMB).
[More]
In patients with human papillomavirus-associated tonsillar carcinoma, second tumors in the contralateral tonsil are typically caused by the same viral variant, a case series indicates.
[More]
Two Duke researchers are focusing on the deadly mathematics behind the mutated genes and damaged cells that drive cancer.
[More]
The GAVI Alliance "is to help protect more than 180,000 girls in eight countries across Africa and Asia from cervical cancer by funding immunization projects with vaccines from Merck and GlaxoSmithKline," Reuters reports in an article examining the group's efforts to vaccinate young women with Merck's Gardasil and GSK's Cervarix, "the world's only two approved shots designed to protect against the sexually transmitted human papillomavirus (HPV) that causes the vast majority of cervical cancer cases."
[More]
More than half of all countries worldwide are struggling to prevent cancer and provide treatment and chronic care to cancer patients, warns a recent World Health Organization (WHO) survey for World Cancer Day. This means, currently many of these countries do not have a functional cancer control plan that includes prevention, early detection, treatment and care. There is an urgent need to help countries to reduce cancer deaths and provide appropriate long-term treatment and care to avoid human suffering and protect countries’ social and economic development.
[More]
Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2012.
[More]
Here at the London School of Hygiene and Tropical Medicine we are running a project called the Vaccine Confidence Project and we have a global surveillance monitoring information around the world on media, social media, all sorts of information, reports from governments, UN, other sources, looking for any what we call “signals” of public distrust or concerns that come up.
[More]
As the number of women in the military increases, so does the need for improved gynecologic care. Military women may be more likely to engage in high-risk sexual practices, be less likely to consistently use barrier contraception, and, therefore, more likely to contract sexually transmitted infections (STIs), according to research recently released by a physician at Women & Infants Hospital of Rhode Island.
[More]